SITE002-0153

SITE002 (USA) › SITE002-0153

SITE002-0153

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE002 (USA) · Dr. Nolan
consented 2026-03-04

enrolled

AEs

5

Serious

0

Dropout signal

–

Adverse events

5

Grade 1 Asthenia — outcome: RECOVERED/RESOLVED; onset 2023-02-28 (study day 169); relationship: NOT RELATED

mild assessed

Grade 1 Hypothyroidism — outcome: RECOVERED/RESOLVED; onset 2023-01-07 (study day 117); relationship: not assessed

mild assessed

Grade 2 Constipation — outcome: RECOVERED/RESOLVED; onset 2022-12-26 (study day 105); relationship: not assessed

moderate assessed

Grade 2 Hypothyroidism — outcome: RECOVERED/RESOLVED; onset 2022-12-17 (study day 96); relationship: not assessed

moderate assessed

Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-12-09 (study day 88); relationship: not assessed

moderate assessed

Data queries

0

No data queries. Open queries would appear here for this patient.